Each year, health recommendations for travelers are evolving to adapt to new global infectious risks. In June 2025, the High Council for Public Health published an entirely updated version, incorporating the latest epidemiological data, the new available vaccines and concrete tools to better protect travelers, depending on their age, their state of health and their destination. We take stock.
Chikungunya: two vaccines, two uses
The HCSP now recommends two different vaccines against chikungunya:
- IXCHIQ, an attenuated living vaccine used in response to the epidemic that occurred in Reunion in the spring of 2025, where more than 51,000 cases were confirmed. Contraindicated among those over 65 with comorbidities, it remains recommended for those under 65 with risk factors, in an epidemic zone or for expatriation;
- Vimkunya, a non -alive viral pseudoparticles vaccine, well tolerated according to clinical trials. It is recommended for those under 65 with comorbidities, and can be envisaged for other profiles if the trip justifies it.
Dengue: qdenga, a prescription under conditions
The Living Vaccine attenuated Qdenga is now supervised by a decision -making logram based on age (from 6 years old), the history of dengue, comorbidities and the epidemiological situation.
- Vaccinal diagram: two subcutaneous doses spaced at least three months;
- Contraindications: immunocompromised people, pregnant or lactating women;
- Key information to be transmitted: minimal delay of two weeks after the first dose to be protected, lower efficiency against serotypes 3 and 4, risk of severe dengue in the event of post-vaccine primary infection, and imperative maintenance of mosquito repellents.
MPOX: extension of vaccination
Faced with the circulation of the IB clade in the Democratic Republic of Congo, the vaccine recommendations widen. Vaccination is now advised to exposed professionals (health, humanitarian, expatriates), travelers at risk of sexual transmission, and people visiting their families in areas where IA or IB clades circulate.
Polio: vigilance on endemic areas
Polio due to the PSV1 wild stump remains endemic in Afghanistan and Pakistan. After only 5 cases in 2021, 99 cases were identified in 2024 and 3 since the beginning of 2025.
The HCSP updates the list of countries concerned and introduces a decision -making logram to guide vaccination according to the obligations of the international health regulations.
Rage: a light preventive scheme
The pre -exhibition vaccination scheme is now simplified:
- Two doses on D0 and J7 are enough, except in immunocompromised (3 recommended doses);
- In the event of a diagram in 2 doses in the immunocompromised, a serological control is essential 2 to 4 weeks after the first dose to determine the need for a third injection.
This simplified pattern facilitates travel protection by reducing the use of immunoglobulins, often unavailable locally.
Measles: recommended catch -up
WHO has alerted since February 2024 to the global resurgence of measles. The HCSP recommends:
- A third dose for people who have received a dose before the age of one year;
- A catch -up vaccination before departure for people born before 1980 with no history of measles or proof of vaccination.
These recommendations target stays in countries where measles remains endemic.
Oropouche: alert on an expanding virus
The Oropouche virus, transmitted by a Moucheron (paraensis asshole), extends from the forests of Latin America to the cities, and reached Cuba in 2024. It causes acute fevers with neurological or hemorrhagic risks.
In the event of an active epidemic, the HCSP advises against any trip to these areas to pregnant women or wishing to become. Prevention is based on anti-insect protection and clear information on risks.
Malaria: always a major threat
Since 2015, the drop in malaria cases has stagnated, and their number has increased since 2020. In France, 6,160 imported cases have been recorded in 2024, 87 % of which are from people from sub -Saharan Africa returning to their country of origin.
- In Guyana, cases are concentrated in gold panning areas, especially in Kourou;
- In Mayotte, no indigenous case has been identified since July 2020.
The HCSP insists on the importance of rapid diagnosis and suitable chemoprophylaxis.
Tuberculosis: New mapping of risk areas
The list of countries with a strong tuberculous impact (more than 40 cases per 100,000 inhabitants) is updated:
- All of Africa except Togo and Tunisia;
- Whole Asia except Japan and South Korea;
- Certain areas of Oceania (Papua Nouvelle-Guinée, Solomon Islands), the Middle East and the Caribbean;
- Several countries in Latin America (Brazil, Colombia, Peru, etc.) and Eastern Europe (Ukraine, Moldova, Romania).
Travelers from or intended for these regions require a specific assessment.
Angiostrongylosis: watch out for the giant snail
This parasitic disease transmitted by the African giant snail (Purchase Fulica) causes eosinophilic meningitis. Endemic in intertropical zones, it can affect children via direct contact with the snail drool.
The HCSP recommends rigorous food education: do not consume invertebrates or raw fish, avoid contaminated raw vegetables, and prohibit the handling of these snails for young children.
Seasonal flu: 2025-2026 vaccine formula
The vaccine for the 2025-2026 season will be trivalent inactivated, without strain B/Yamagata, in accordance with the evolution of the composition recommended by the WHO.